Physician profile
Stephen M Miller
NPI 1871519660
$1,535.87
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $181 · 2021: $369 · 2022: $183 · 2023: $311 · 2024: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.97 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $271.15 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $168.22 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $139.15 | 2021-2024 | |
| Allergan, INC. | $124.73 | 2020 | |
| Amgen INC. | $114.01 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $106.38 | 2019-2024 | |
| Abbott Laboratories | $63.74 | 2023-2024 | Freestyle Libre 2 |
| Amarin Pharma, INC. | $61.16 | 2021 | |
| Genentech USA, INC. | $34.04 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $28.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.91 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $18.79 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $18.63 | 2024 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.